Peptide class
Peptides investigated for their roles in reproductive biology, sexual function, and hormonal axis regulation — including compounds acting on the hypothalamic-pituitary-gonadal (HPG) axis and the melanocortin system. Distinct mechanistic pathways that both intersect with fertility and sexual health research.
| Compound | Mechanism | Primary reported use | Profile |
|---|---|---|---|
| Kisspeptin | KISS1 gene product; GPR54 (KISS1R) agonist; stimulates GnRH pulse release from hypothalamic neurons; upstream regulator of LH, FSH, and gonadal steroid production | HPG axis modulation, fertility research, hypogonadism, testosterone support | View profile |
| PT-141 | Melanocortin peptide (Bremelanotide); MC3R and MC4R agonist; central nervous system–mediated sexual arousal pathways | Sexual arousal, hypoactive sexual desire disorder (HSDD); FDA-approved pharmaceutical (Vyleesi) for premenopausal women | View profile |
The compounds in this class act through distinct but complementary pathways in reproductive and sexual function research. Kisspeptin operates at the hypothalamic level — the apex of the HPG (hypothalamic-pituitary-gonadal) axis — stimulating GnRH-secreting neurons via the GPR54 receptor. Pulsatile GnRH release then drives the pituitary to secrete LH and FSH, which in turn stimulate gonadal steroid production (testosterone in males; oestradiol and progesterone in females). Kisspeptin is thus a proximal regulator of the entire reproductive hormonal cascade.
PT-141 (Bremelanotide) operates through a fundamentally different mechanism: it is a melanocortin receptor agonist, acting primarily at MC3R and MC4R receptors in the central nervous system. Rather than regulating the HPG axis and steroid production, PT-141 modulates the neural pathways underlying sexual arousal and desire — acting centrally rather than peripherally. This distinguishes it from phosphodiesterase inhibitors (sildenafil, tadalafil), which act peripherally on vascular smooth muscle; PT-141 targets CNS arousal pathways directly.
The two mechanisms address different aspects of reproductive and sexual health: Kisspeptin targets hormonal axis function and fertility, while PT-141 targets sexual arousal and desire. They are potentially complementary in research settings where both hormonal support and arousal modulation are of interest, though they are typically studied independently.
Kisspeptin's role as a master regulator of the HPG axis was discovered in 2003, following the identification of the KISS1 gene and its receptor GPR54 as critical for normal pubertal development and reproductive function. Loss-of-function mutations in GPR54 were found to cause idiopathic hypogonadotropic hypogonadism — a condition where the HPG axis fails to activate properly — establishing kisspeptin signalling as essential for reproductive function. Research has since investigated kisspeptin for its potential role in the treatment of hypogonadism, fertility disorders, and as a tool to study GnRH pulse dynamics.
PT-141 (Bremelanotide) was developed from the broader melanocortin research programme that also produced Melanotan I and Melanotan II. Unlike MT-II, which was developed primarily for pigmentation and has a broad receptor profile, PT-141 was specifically optimised for the sexual arousal indication through MC3R and MC4R receptor activity. It received FDA approval in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few research-community peptides to have achieved pharmaceutical approval for a sexual health indication.
Kisspeptin
Kisspeptin-10 is the shortest, most commonly described isoform in research contexts; Kisspeptin-54 is the primary circulating form and most used in clinical trials. Research has investigated kisspeptin for its potential role in hypogonadotropic hypogonadism, male fertility, female reproductive cycle regulation, and testosterone support. Commonly reported research protocols describe subcutaneous or intravenous administration. Not approved as a pharmaceutical; classified as a research compound.
PT-141 (Bremelanotide)
FDA-approved as Vyleesi (1.75 mg subcutaneous auto-injector) for HSDD in premenopausal women. Research community use extends to a wider range of doses and indications. Commonly reported doses range from 500 mcg to 2 mg subcutaneously. Reported side effects in research and anecdotal accounts include nausea (the most common), facial flushing, transient hyperpigmentation with repeated use, and transient blood pressure elevation.